MedTrace Logo

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2100

Last updated 2025-07-11

No results posted yet for this study

Summary

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Conditions

  • Frontotemporal Lobar Degeneration (FTLD)
  • Progressive Supranuclear Palsy (PSP)
  • Corticobasal Degeneration (CBD)
  • Behavioral Variant Frontotemporal Dementia (bvFTD)
  • Semantic Variant Primary Progressive Aphasia (svPPA)
  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
  • FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)
  • Amyotrophic Lateral Sclerosis
  • Oligosymptomatic PSP (oPSP)
  • C9orf72
  • GRN Related Frontotemporal Dementia
  • MAPT Gene Mutation
  • TBK1 Gene Mutation
  • Oligosymptomatic Progressive Supranuclear Palsy

Sponsors & Collaborators

Principal Investigators

  • Bradley Boeve, MD · Mayo Clinic

  • Adam Boxer, MD, PhD · University of California, San Francisco

  • Howie Rosen, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04363684 on ClinicalTrials.gov